FIGURE 4
FROM:
Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia
J D Gibbs, D A Liebermann and B Hoffman
BACK TO ARTICLEFigure 4.
Growth kinetics and cell cycle analysis of cells treated with interleukin-6 (IL-6). (a) At indicated time points, viable cell numbers were determined using a hemocytometer. Results are the average of three independent experiments with s.d. up to 15%. (
) M1; (
) M1Egr-1; (*) M1E2F/Egr#1; (
) M1E2F/Egr#2. (b) Cell cycle analysis by flow cytometry on cells treated with or without IL-6 for 3 days. This is a representative experiment, done four times, showing distribution of cells in cell cycle. There is a significant reduction of cells in S phase of IL-6-treated M1E2F-1/Egr-1 cells compared to IL-6-treated M1E2F-1 (P<0.05). The profiles of IL-6-treated M1E2F-1 and M1E2F-1/Egr-1 cells are shown below.